Business Valuation: Medical Manufacturing (Contract)

The average Swiss Medical Manufacturing (Contract) company is valued at 5.5 - 7.5× EBITDA on a statutory (tax-based) basis and 7.0 - 10.0× EBITDA in actual deal transactions. The spread between statutory and deal multiples represents a key arbitrage opportunity for informed buyers. The current market trend is rising, with an arbitrage gap rated as medium. Actual valuations depend heavily on recurring revenue share, customer diversification, management depth, and equipment modernity.

Key valuation drivers include: Certification is a durable moat. ISO 13485 quality systems, EU MDR technical files, Swissmedic oversight and customer approvals take years to build and do not transfer with a cheaper quotation; Among the highest export ratios of any Swiss industry: Swiss Medtech reports that goods exports from the sector account for 11.9% of Switzerland's positive trade balance. Factors that can compress valuations include: Tariff exposure that changed four times in eighteen months. Since 24 July 2026 imports from Switzerland face a 12.5% Section 301 rate where the most-favoured-nation rate is lower, and the higher MFN rate where it is not — so the burden differs product by product and cannot be planned as a single number; Regulatory cost is structural and rising. EU MDR conformity, Swissmedic oversight, FDA registration and the Cyber Resilience Act transition running to 2027 all fall on the same quality organisation, which in an SME is a handful of people. Deal multiples typically range from 7.0 - 10.0× EBITDA, but actual prices vary significantly based on customer concentration, management quality, revenue predictability, and geographic reach within Switzerland's 26 cantons.

There is no official count of Swiss medical device manufacturers, and the roughly 1,400 firms commonly cited — including in the February 2026 edition of this report — is an estimate. What Swiss Medtech does publish is the structural fact that matters most: 95% of the industry is SMEs. The nearest measured statistic is BFS STATENT 2024, published 20 August 2026, which records 3,752 establishments and 30,364 employees in NOGA division 32 "other manufacturing" — the division containing medical and dental instruments, but also jewellery, sports goods and musical instruments, so it is an outer bound rather than a count. Division 32 employment is up 2.0% since 2022 and 14.6% since 2012, while machinery fell 1.1% and electrical equipment 24.0% over the same twelve years. Two caveats on vintage: the Swiss Medtech SMTI industry study publishes its 2026 edition on 9 September 2026 in Bern, so any sector figure quoted before that date predates the current study; and the commercial register is the reliable check on any individual name — there is no Swiss entry for Rüeger SA, listed as a key player in earlier editions of this report, and Jabil's Swiss operations are Jabil Switzerland Manufacturing GmbH in Hägendorf (SO) with a registered branch in Le Locle.

Swiss Medtech classifies 95% of its industry as SMEs, which makes medical manufacturing one of the deepest succession pools in Swiss industry — and one of the most technically difficult to transfer. What a buyer acquires is not machine capacity but a regulatory position: ISO 13485 certification, EU MDR technical files, Swissmedic registration, FDA listings, validated processes and an audit history that a notified body has already accepted. All of it attaches to the company on paper and to two or three named people in practice, and if it lapses, rebuilding costs twelve to twenty-four months during which the customer relationship is exposed. The regulatory load is also still rising: alongside MDR conformity and Swissmedic oversight, the Cyber Resilience Act transition runs to 2027, and it lands on the same small quality organisation. The trading environment is more favourable than the headline suggests. Swissmem's H1 2026 data show medtech exports down only 1.8%, the mildest decline in the tech industry, and Swiss Medtech reports the sector accounts for 11.9% of Switzerland's positive trade balance. But two things should shape timing. First, the US tariff position changed on 24 July 2026 to a product-specific regime — 12.5% under Section 301 where the most-favoured-nation rate is lower, the MFN rate where it is higher — and Swiss Medtech notes that ongoing Section 301 investigations could bring more. Second, the Swiss Medtech SMTI 2026 industry study publishes on 9 September 2026, and a seller preparing a process should have its figures rather than the prior edition's. Owners should treat certification continuity as the first line of the succession plan, name and document the regulatory lead's knowledge explicitly, and allow two to three years of overlap. Deal multiples for the sector typically run 7.0 - 10.0× EBITDA.

Four trends define the sector in 2026: (1) The US tariff on Swiss medtech is now product-specific, at 12.5% or the MFN rate — Swiss Medtech's tariff portal records the sequence: at the end of February 2026 the US Supreme Court ruled the reciprocal tariffs imposed under emergency powers unlawful; during a 150-day transition period imports into the United States from all countries carried a flat additional 10 percent; and on expiry of that peri (2) Bern is negotiating on standards recognition, not just on rates — On 30 June 2026, as part of an economic and scientific mission to the United States, the Federal Council submitted a statement to the US Trade Representative arguing that the Swiss economy needs legal certainty. (3) Every sector figure is provisional until 9 September 2026 — The Swiss Medtech SMTI industry study publishes its 2026 edition on 9 September 2026 in Bern. (4) A sector that is 95% SME, with regulation as the transfer risk — Swiss Medtech classifies 95% of its industry as SMEs. That makes Swiss medtech manufacturing an unusually deep acquisition pool relative to its revenue — and it puts the sector's hardest succession problem in sharp relief.

The principal acquisition risks are: (1) Section 301 uncertainty persists. Swiss Medtech notes that ongoing US Section 301 investigations could still produce additional trade policy measures beyond the 12.5% rate effective 24 July 2026; (2) The Joint Statement concluded in November 2025 and its maximum 15% rate depend on mutual compliance, and Swiss exporters carry the downside if that unwinds; (3) EU market access remains regulatory rather than automatic, and MDR conformity costs fall hardest on small manufacturers with narrow product ranges over which to spread them. Buyers should conduct thorough due diligence on customer concentration, regulatory compliance, and key-person dependencies. Deal multiples of 7.0 - 10.0× EBITDA may be discounted for firms with elevated risk profiles.

The typical cost breakdown for a Swiss Medical Manufacturing (Contract) firm is: Raw Materials (titanium, cobalt-chrome, PEEK, precious metals): 28%, Personnel Costs (cleanroom operators, engineers, QA): 35%, Cleanroom Operations & Validation: 10%, Regulatory Compliance & Quality Systems: 8%, Equipment Depreciation & Maintenance: 9%, Profit Margin (EBITDA): 10%. Indicative split for a Swiss medical device manufacturer or contract producer. Two lines behave differently from general manufacturing. Cleanroom operations and validation are a fixed cost that only pays back at volume, and regulatory compliance and quality systems are recurring rather than one-off: EU MDR conformity, Swissmedic oversight, FDA registration and the Cyber Resilience Act transition running to 2027 all fall on the same quality organisation, which in an SME is a handful of people. On the input side, the tariff position changed on 24 July 2026 to a product-specific US regime — 12.5% under Section 301 where the most-favoured-nation rate is lower, the MFN rate where it is higher — so landed cost now differs product by product. Swissmem reported tech industry capacity utilisation of 81.1% in Q2 2026 against a long-run average of 85.6% (2015-2025), with medtech exports down 1.8% in H1 2026, the mildest decline in the sector. These benchmarks are important for buyers assessing operational efficiency and margin improvement potential post-acquisition.

Switzerland's main Medical Manufacturing (Contract) clusters are: (1) Bern and Biel/Bienne (BE) — The densest medtech corridor in Switzerland, and the one where watchmaking precision converted most directly into medical device manufacturing. (2) Solothurn implant belt (SO) — Orthopaedic implants and regulated contract manufacturing. Mathys AG Bettlach in Bettlach builds hip, knee and shoulder arthroplasty implants and instruments, and Jabil Switzerland Manufacturing GmbH in Hägendorf runs contract manufacturing for healthcare and other regulated markets. (3) Basel region (BS, BL) — Implant systems next to the pharmaceutical cluster. Medartis AG and Medartis Holding AG are registered in Basel, building osteosynthesis plates and screws for craniomaxillofacial and extremity surgery; Medartis won the Swiss Medtech Award 2026. (4) Jura arc and Lake Geneva (JU, NE, GE) — Surgical instruments and implants at the French-speaking end of the country. Regional concentration affects valuations, as companies in established clusters benefit from supplier ecosystems, specialized talent pools, and industry networks.